Table 1.

Distribution of cs-DMARD first-line, b-DMARD first-line, and combination by active agent in DMARD new users.

	cs-DMARDfirst-line			b-DMARDfirst-line				Total
				Alone		In combination with cs
Active agents	ATC	N	%	N	%	N	%	N	%
Methotrexate	L01BA01/L04AX03	2985	59.3					2985	55.0
Hydroxycloroquine	P01BA02	1337	26.5					1337	24.7
Sulfasalazine	A07EC01	533	10.6					533	9.8
Leflunomide	L04AA13	182	3.6					182	3.4
Etanercept	L04AB01			109	32.4	34	66.7	143	2.6
Adalimumab	L04AB04			73	21.7	9	17.7	82	1.5
Rituximab	L01XC02			43	12.8	0	0.0	43	0.8
Anakinra	L04AC03			31	9.2	3	5.9	34	0.6
Tocilizumab	L04AC07			25	7.4	4	7.8	29	0.5
Abatacept	L04AA24			17	5.1	0	0.0	17	0.3
Certolizumabpegol	L04AB05			15	4.5	1	2.0	16	0.3
Infliximab	L04AB02			9	2.7	0	0.0	9	0.2
Golimumab	L04AB06			14	4.2	0	0.0	14	0.3
Total		5037	100.0	336	100.0	51	100.0	5424	100.0

b-DMARDs = biological-DMARDs, cs-DMARDs = conventional synthetic-DMARDs, DMARDs = disease modifying anti-rheumatic drugs.